<DOC>
	<DOCNO>NCT01383928</DOCNO>
	<brief_summary>This phase 1/2 , multicenter , open-label study use oral formulation IXAZOMIB administer twice weekly combination lenalidomide low-dose dexamethasone . Both phase study include patient newly diagnose multiple myeloma previously receive systemic treatment . Both phase 1 phase 2 portion study include induction therapy consist 1 year therapy follow maintenance therapy continue progressive disease unacceptable toxicity . Maintenance therapy IXAZOMIB alone Days 1,4,8 , &amp; 11 21-day cycle .</brief_summary>
	<brief_title>Study Oral IXAZOMIB Combination With Lenalidomide Dexamethasone Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female patient 18 year older Symptomatic multiple myeloma asymptomatic myeloma myelomarelated organ damage diagnose accord standard criterion Measurable disease specify study protocol Hematologic , liver , renal function specify study protocol . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception agree abstain heterosexual intercourse ; must also adhere guideline lenalidomide pregnancy prevention program Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse AND must adhere guideline lenalidomide pregnancy prevention program Must able take concurrent aspirin 325 mg daily Voluntary write consent Exclusion Criteria Peripheral neuropathy great equal Grade 2 Female patient lactate pregnant Major surgery radiotherapy within 14 day first dose study drug Uncontrolled infection require systematic antibiotic within 14 day first dose study drug Diarrhea ( &gt; Grade 1 ) Prior systemic therapy multiple myeloma , include investigational drug ( prior treatment corticosteroid localize radiation therapy dose disqualify patient ) Systemic treatment strong inhibitor CYP1A2 , strong inhibitor CYP3A , strong CYP3A inducer , use Ginkgo biloba St. John 's wort within 14 day first dose study treatment Central nervous system involvement Diagnosis smolder multiple myeloma , Waldenstrom 's macroglobulinemia , POEMS syndrome , plasma cell leukemia , primary amyloidosis , myelodysplastic syndrome , myeloproliferative syndrome Evidence current uncontrolled cardiovascular condition Prior concurrent deep vein thrombosis pulmonary embolism Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive status , know suspect active hepatitis C infection Serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol Known allergy study medication Known gastrointestinal condition procedure could interfere swallow oral absorption , tolerance IXAZOMIB Diagnosed treat another malignancy within 2 year first dose previously diagnose another malignancy evidence residual disease exception nonmelanoma skin cancer completely resect carcinoma situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>